Alfred Health Radiation Oncology Services, Melbourne, Victoria, Australia.
Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia.
J Med Imaging Radiat Oncol. 2022 Sep;66(6):830-839. doi: 10.1111/1754-9485.13407. Epub 2022 Mar 31.
To evaluate the proportion of cancer patients who received radiation therapy (RT) within 12 months of cancer diagnosis (RTU12) and identify factors associated with RTU12.
This is a population-based cohort of individuals with incident cancer, diagnosed between 2013 and 2017 in Victoria. Data linkages were performed between the Victorian Cancer Registry and Victorian Radiotherapy Minimum Dataset. The primary outcome was the proportion of patients who had RTU12. For the three most common cancers (i.e., prostate, breast and lung cancer), the time trend in RTU12 and factors associated with RTU12 were evaluated.
The overall RTU12 in our study cohort was 26-20% radical RT and 6% palliative RT. Of the 21,735 men with prostate cancer, RTU12 was 17%, with no significant change over time (P-trend = 0.53). In multivariate analyses, increasing age and lower socioeconomic status were independently associated with higher RTU12 for prostate cancer. Of the 20,883 women with breast cancer, RTU12 was 64%, which increased from 62% in 2013 to 65% in 2017 (P-trend < 0.05). In multivariate analyses, age, socioeconomic status and area of residency were independently associated with RTU12 for breast cancer. Of the 13,093 patients with lung cancer, RTU12 was 42%, with no significant change over time (P-trend = 0.16). In multivariate analyses, younger age, male and lower socioeconomic status were independently associated with higher RTU12.
In this large population-based state-wide cohort of cancer patients, only 1 in 4 had RT within 12 months of diagnosis. There were marked sociodemographic disparities in RTU12 for prostate, breast and lung cancer patients.
评估癌症患者在癌症诊断后 12 个月内接受放射治疗(RT)的比例(RTU12),并确定与 RTU12 相关的因素。
这是一项基于人群的队列研究,纳入了 2013 年至 2017 年期间在维多利亚州诊断出的癌症患者。通过维多利亚癌症登记处和维多利亚放射治疗最低数据集进行数据链接。主要结局是接受 RTU12 的患者比例。对于三种最常见的癌症(即前列腺癌、乳腺癌和肺癌),评估了 RTU12 的时间趋势和与 RTU12 相关的因素。
我们研究队列的总体 RTU12 为 26-20%的根治性 RT 和 6%的姑息性 RT。在 21735 名男性前列腺癌患者中,RTU12 为 17%,且随时间无显著变化(趋势 P 值=0.53)。在多变量分析中,年龄增长和社会经济地位降低与前列腺癌的更高 RTU12 独立相关。在 20883 名女性乳腺癌患者中,RTU12 为 64%,从 2013 年的 62%增加到 2017 年的 65%(趋势 P 值<0.05)。在多变量分析中,年龄、社会经济地位和居住地区与乳腺癌的 RTU12 独立相关。在 13093 名肺癌患者中,RTU12 为 42%,且随时间无显著变化(趋势 P 值=0.16)。在多变量分析中,年龄较小、男性和社会经济地位较低与更高的 RTU12 独立相关。
在这项基于人群的大型全州癌症患者队列研究中,只有 1/4 的患者在诊断后 12 个月内接受 RT。前列腺癌、乳腺癌和肺癌患者的 RTU12 存在显著的社会人口统计学差异。